Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof

US11261259B2 · kind B2 · utility

Assignees

• I-MAB BIOPHARMA US LIMITED · US
• ABL BIO INC. · KR

Inventors

• Wenqing Jiang · Shanghai, CN
• Lei Fang · Katy, US
• Zhengyi Wang · Shanghai, CN
• Bingshi Guo · Shanghai, CN
• Eunyoung Park · Daega-myeon, KR
• Eunsil Sung · Seongnam-si, KR
• Byungje Sung · Seongnam-si, KR

Key dates

• Filing date: Aug 12, 2020
• Grant date: Mar 1, 2022
• Expiry date: Aug 12, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.